สำนักงานราชบัณฑิตยสภา

บิ สฟอสโฟเนตและการตายของกระดูกขากรรไกรบางส่วน 102 The Journal of the Royal Institute of Thailand Vol. 38 No. 3 July-Sep 2013 Olutayo J, Agbaje JO, Jacobs R, Verhaeghe V, Velde FV and Vinckier F. Bisphosphonate-related Osteonecrosis of the Jaw Bone: Radiological pattern and the potential role of CBCT in early diagnosis. J Oral Maxillofac Res 2010, [Apr-Jun]1: e3. Reuther T, Schuster, Mende U, Kubler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients—a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 2003: 32; 289-295. Rizzolo D, Sedrak M. Managing the adverse effects of bisphosphonate therapy on the jaw. JAAPA 2009, 22; 48-52. Robinson NA. Bisphosphonates-A word of caution. Ann Acadof Med Singapore 2004; 33[suppl]: 48S-49S. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates Cancer 1997: 80 [supplement8]: 1652-60. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates; a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 1238-9. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American association of oral and maxillofacial surgeons position paper on bisphosphonated osteonecrosis of the jaws 2009 update. J Oral Maxillofac Surg 2009; 67: 2-12. Russell RG. Rogers MJ, Frith JC et al. The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res 1999; 14 [supplement 2] 53-65. Santini D, Vincenci B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, et al. Zoledronic acidinduces significant and long lasting modifications of circulating angiogenic factors in caner patients. Clin Cancer Res 2003; 9: 2893-7. Sparidans RW, Twiss IM, Talbot S. Bisphosphonate in bone diseases. PharmWorld Sci 1998; 20: 206-213.